{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:47:08Z","timestamp":1792691228598,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030_201199"],"award-info":[{"award-number":["310030_201199"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>BOK is a pro-apoptotic member of the BCL-2 family frequently repressed in cancer and with emerging roles beyond apoptosis. BOK interacts with and increases uridine monophosphate synthetase (UMPS) activity, thereby promoting uridine monophosphate (UMP) synthesis. We previously showed that BOK protein is downregulated in primary human lung cancer samples, correlating with poorer patient survival. Here, we demonstrate that BOK deficiency increases DNA damage, triggering p53 activation and cell cycle arrest in two independent non-small cell lung cancer (NSCLC) cell models that express either WT or defective p53. In a p53-deficient setting, BOK loss caused elevated baseline DNA damage rendering cells more dependent on alternative DNA repair pathways. We exploited this vulnerability by inhibiting the ATR-mediated DNA damage response pathway with the selective ATR inhibitor ceralasertib (AZD6738). ATR inhibition in BOK\/p53 compound-deficient NSCLC cells exacerbated DNA damage and induced cell death, indicating a synthetic lethal interaction. The DNA damage in BOK-deficient cells was rescued by a cell permeable BOK-BH3-derived peptide, confirming the mechanistic link between BOK and UMPS. Taken together, our findings reveal a vulnerability in NSCLC, where combined loss of p53 and BOK sensitises cells to ATR inhibition. This synthetic interaction suggests that p53-deficient tumours with reduced BOK expression may be more reliant on ATR-mediated DNA repair, providing a mechanistic basis for their susceptibility to ATR inhibitors. Given the frequent inactivation of p53 in lung cancer, our study offers a rationale for clinical exploration of ATR inhibitors, in combination with standard chemotherapy, in the context of reduced BOK function. Future investigations into the broader role of BOK in genomic stability and nucleotide metabolism may uncover additional therapeutic strategies for cancers with repressed BOK.<\/jats:p>","DOI":"10.1038\/s41418-026-01666-0","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T10:50:29Z","timestamp":1769683829000},"page":"1878-1890","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Loss of BOK increases vulnerability of p53 deficient non-small cell lung cancer cells to ATR inhibition through its role in uridine metabolism"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9005-1211","authenticated-orcid":false,"given":"Philippe","family":"JeanRichard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Ananthanarayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6930-1993","authenticated-orcid":false,"given":"Liyang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Jazaeri Jouneghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6635-7312","authenticated-orcid":false,"given":"Daniel","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9906-874X","authenticated-orcid":false,"given":"Thomas","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"1666_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1126\/science.1081208","volume":"300","author":"L Scorrano","year":"2003","unstructured":"Scorrano L, Oakes SA, Opferman JT, Cheng EH, Sorcinelli MD, Pozzan T, et al. BAX and BAK Regulation of Endoplasmic Reticulum Ca2\u2009+\u2009: A Control Point for Apoptosis. Science. 2003;300:135\u20139.","journal-title":"Science"},{"key":"1666_CR2","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrc883","volume":"2","author":"S Cory","year":"2002","unstructured":"Cory S, Adams JM. The BCL2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2:647\u201356.","journal-title":"Nat Rev Cancer"},{"key":"1666_CR3","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/sj.onc.1210220","volume":"26","author":"JM Adams","year":"2007","unstructured":"Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26:1324\u201337.","journal-title":"Oncogene"},{"key":"1666_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/cdd.2017.161","volume":"25","author":"JM Adams","year":"2018","unstructured":"Adams JM, Cory S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 2018;25:27\u201336.","journal-title":"Cell Death Differ"},{"key":"1666_CR5","first-page":"443","volume":"2","author":"S Cory","year":"2016","unstructured":"Cory S, Roberts AW, Colman PM, Adams JM. Targeting BCL-2-like Proteins to Kill Cancer Cells. Trends. Cancer. 2016;2:443\u201360.","journal-title":"Cancer"},{"key":"1666_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41580-019-0173-8","volume":"21","author":"FJ Bock","year":"2020","unstructured":"Bock FJ, Tait SWG. Mitochondria as multifaceted regulators of cell death. Nat Rev Mol Cell Biol. 2020;21:85\u2013100.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1666_CR7","doi-asserted-by":"publisher","first-page":"12401","DOI":"10.1073\/pnas.94.23.12401","volume":"94","author":"SY Hsu","year":"1997","unstructured":"Hsu SY, Kaipia A, Mcgee E, Lomeli M, W Hsueh AJ. Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members. Proc Natl Acad Sci USA. 1997;94:12401\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1666_CR8","doi-asserted-by":"publisher","first-page":"11820","DOI":"10.1074\/jbc.M115.711242","volume":"291","author":"JJ Schulman","year":"2016","unstructured":"Schulman JJ, Wright FA, Han X, Zluhan EJ, Szczesniak LM, Wojcikiewicz RJH. The stability and expression level of Bok are governed by binding to inositol 1,4,5-trisphosphate receptors. J Biol Chem. 2016;291:11820\u20138.","journal-title":"J Biol Chem"},{"key":"1666_CR9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/cdd.2013.10","volume":"20","author":"N Echeverry","year":"2013","unstructured":"Echeverry N, Bachmann D, Ke F, Strasser A, Simon HU, Kaufmann T. Intracellular localization of the BCL-2 family member BOK and functional implications. Cell Death Differ. 2013;20:785\u201399.","journal-title":"Cell Death Differ"},{"key":"1666_CR10","doi-asserted-by":"publisher","first-page":"108827","DOI":"10.1016\/j.celrep.2021.108827","volume":"34","author":"MA Carpio","year":"2021","unstructured":"Carpio MA, Means RE, Brill AL, Sainz A, Ehrlich BE, Katz SG. BOK controls apoptosis by Ca(2+) transfer through ER-mitochondrial contact sites. Cell Rep. 2021;34:108827.","journal-title":"Cell Rep"},{"key":"1666_CR11","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/cdd.2011.210","volume":"19","author":"F Ke","year":"2012","unstructured":"Ke F, Voss A, Kerr JB, O\u2019Reilly LA, Tai L, Echeverry N, et al. BCL-2 family member BOK is widely expressed but its loss has only minimal impact in mice. Cell Death Differ. 2012;19:915\u201325.","journal-title":"Cell Death Differ"},{"key":"1666_CR12","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463:899\u2013905.","journal-title":"Nature"},{"key":"1666_CR13","doi-asserted-by":"publisher","first-page":"574338","DOI":"10.3389\/fcell.2020.574338","volume":"8","author":"S Naim","year":"2020","unstructured":"Naim S, Kaufmann T. The Multifaceted Roles of the BCL-2 Family Member BOK. Front Cell Dev Biol. 2020;8:574338.","journal-title":"Front Cell Dev Biol"},{"key":"1666_CR14","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1002\/ijc.30906","volume":"141","author":"E Moravcikova","year":"2017","unstructured":"Moravcikova E, Krepela E, Donnenberg VS, Donnenberg AD, Benkova K, Rabachini T, et al. BOK displays cell death-independent tumor suppressor activity in non-small-cell lung carcinoma. Int J Cancer. 2017;141:2050\u201361.","journal-title":"Int J Cancer"},{"key":"1666_CR15","doi-asserted-by":"publisher","first-page":"15469","DOI":"10.1073\/pnas.1904523116","volume":"116","author":"R Srivastava","year":"2019","unstructured":"Srivastava R, Cao Z, Nedeva C, Naim S, Bachmann D, Rabachini T, et al. BCL-2 family protein BOK is a positive regulator of uridine metabolism in mammals. Proc Natl Acad Sci USA. 2019;116:15469\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1666_CR16","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.tcb.2023.03.003","volume":"33","author":"ES Ali","year":"2023","unstructured":"Ali ES, Ben-Sahra I. Regulation of nucleotide metabolism in cancers and immune disorders. Trends Cell Biol. 2023;33:950\u201366.","journal-title":"Trends Cell Biol"},{"key":"1666_CR17","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1111\/j.1742-4658.2010.07573.x","volume":"277","author":"S Levitte","year":"2010","unstructured":"Levitte S, Salesky R, King B, Smith SC, Depper M, Cole M, et al. A Caenorhabditis elegans model of orotic aciduria reveals enlarged lysosome-related organelles in embryos lacking umps-1 function. FEBS J. 2010;277:1420\u201339.","journal-title":"FEBS J"},{"key":"1666_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-022-01263-x","volume":"15","author":"HL Wu","year":"2020","unstructured":"Wu HL, Gong Y, Ji P, Xie YF, Jiang YZ, Liu GY. Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy. J Hematol Oncol. 2020;15:45.","journal-title":"J Hematol Oncol"},{"key":"1666_CR19","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1016\/j.gendis.2022.04.018","volume":"10","author":"J Chen","year":"2023","unstructured":"Chen J, Yang S, Li Y, Ziwen X, Zhang P, Song Q, et al. De novo nucleotide biosynthetic pathway and cancer. Genes Dis. 2023;10:2331\u20138.","journal-title":"Genes Dis"},{"key":"1666_CR20","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.ccell.2024.04.009","volume":"42","author":"Y Liu","year":"2024","unstructured":"Liu Y, Su Z, Tavana O, Gu W. Understanding the complexity of p53 in a new era of tumor suppression. Cancer Cell. 2024;42:946\u201367.","journal-title":"Cancer Cell"},{"key":"1666_CR21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jmcb\/mjz060","volume":"11","author":"Y Liu","year":"2019","unstructured":"Liu Y, Tavana O, Gu W. P53 modifications: Exquisite decorations of the powerful guardian. J Mol Cell Biol. 2019;11:564\u201377.","journal-title":"J Mol Cell Biol"},{"key":"1666_CR22","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/j.celrep.2016.01.059","volume":"14","author":"LJ Valente","year":"2016","unstructured":"Valente LJ, Aubrey BJ, Herold MJ, Kelly GL, Happo L, Scott CL, et al. Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells. Cell Rep. 2016;14:1858\u201366.","journal-title":"Cell Rep"},{"key":"1666_CR23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333\u20139.","journal-title":"Nature"},{"key":"1666_CR24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"EA Collisson","year":"2014","unstructured":"Collisson EA, Campbell JD, Brooks AN, Berger AH, Lee W, Chmielecki J, et al. Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network. Nature. 2014;511:543\u201350.","journal-title":"Nature"},{"key":"1666_CR25","doi-asserted-by":"crossref","unstructured":"Fan Z, Zhang Q, Feng L, Wang L, Zhou X, Han J, et al. Genomic landscape and prognosis of patients with TP53-mutated non-small cell lung cancer. Ann Transl Med. 2022;10:188.","DOI":"10.21037\/atm-22-412"},{"key":"1666_CR26","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1038\/sj.onc.1210302","volume":"26","author":"A Petitjean","year":"2007","unstructured":"Petitjean A, Achatz MIW, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26:2157\u201365.","journal-title":"Oncogene"},{"key":"1666_CR27","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41418-017-0008-0","volume":"25","author":"T Rabachini","year":"2018","unstructured":"Rabachini T, Fernandez-Marrero Y, Montani M, Loforese G, Sladky V, He Z, et al. BOK promotes chemical-induced hepatocarcinogenesis in mice. Cell Death Differ. 2018;25:708\u201320.","journal-title":"Cell Death Differ"},{"key":"1666_CR28","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41388-021-02161-1","volume":"41","author":"AL Meinhardt","year":"2022","unstructured":"Meinhardt AL, Munkhbaatar E, H\u00f6ckendorf U, Dietzen M, Dechant M, Anton M, et al. The BCL-2 family member BOK promotes KRAS-driven lung cancer progression in a p53-dependent manner. Oncogene. 2022;41:1376\u201382.","journal-title":"Oncogene"},{"key":"1666_CR29","doi-asserted-by":"publisher","first-page":"6314","DOI":"10.1073\/pnas.0802080105","volume":"105","author":"K Hastak","year":"2008","unstructured":"Hastak K, Paul RK, Agarwal MK, Thakur VS, Amin AR. DNA synthesis from unbalanced nucleotide pools causes limited DNA damage that triggers ATR-CHK1-dependent p53 activation. PNAS. 2008;105:6314\u201323.","journal-title":"PNAS"},{"key":"1666_CR30","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/s41556-022-00965-1","volume":"24","author":"FF Diehl","year":"2022","unstructured":"Diehl FF, Miettinen TP, Elbashir R, Nabel CS, Darnell AM, Do BT, et al. Nucleotide imbalance decouples cell growth from cell proliferation. Nat Cell Biol. 2022;24:1252\u201364.","journal-title":"Nat Cell Biol"},{"key":"1666_CR31","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.3390\/ijms23031701","volume":"23","author":"W Choi","year":"2022","unstructured":"Choi W, Lee ES. Therapeutic Targeting of DNA Damage Response in Cancer. Int J Mol Sci. 2022;23:1701.","journal-title":"Int J Mol Sci"},{"key":"1666_CR32","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.currproblcancer.2017.05.002","volume":"41","author":"R Sundar","year":"2017","unstructured":"Sundar R, Brown J, Ingles Russo A, Yap TA, Targeting ATR. in cancer medicine. Curr Probl Cancer. 2017;41:302\u201315.","journal-title":"Curr Probl Cancer"},{"key":"1666_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-020-00874-6","volume":"13","author":"P Gralewska","year":"2020","unstructured":"Gralewska P, Gajek A, Marczak A, Rogalska A. Participation of the ATR\/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer. J Hematol Oncol. 2020;13:39.","journal-title":"J Hematol Oncol"},{"key":"1666_CR34","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.1074\/jbc.M806739200","volume":"284","author":"RA Chanoux","year":"2009","unstructured":"Chanoux RA, Yin B, Urtishak KA, Asare A, Bassing CH, Brown EJATR. and H2AX cooperate in maintaining genome stability under replication stress. J Biol Chem. 2009;284:5994\u20136003.","journal-title":"J Biol Chem"},{"key":"1666_CR35","doi-asserted-by":"publisher","first-page":"a012716","DOI":"10.1101\/cshperspect.a012716","volume":"5","author":"A Mar\u00e9chal","year":"2013","unstructured":"Mar\u00e9chal A, Zou L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol. 2013;5:a012716.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1666_CR36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3892\/or.2022.8289","volume":"47","author":"T Suzuki","year":"2022","unstructured":"Suzuki T, Hirokawa T, Maeda A, Harata S, Watanabe K, Yanagita T, et al. ATR inhibitor AZD6738 increases the sensitivity of colorectal cancer cells to 5-fluorouracil by inhibiting repair of DNA damage. Oncol Rep. 2022;47:78.","journal-title":"Oncol Rep"},{"key":"1666_CR37","doi-asserted-by":"publisher","first-page":"44289","DOI":"10.18632\/oncotarget.6247","volume":"6","author":"FP Vendetti","year":"2015","unstructured":"Vendetti FP, Lau A, Schamus S, Conrads TP, O\u2019connor MJ, Bakkenist CJ. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. Oncotarget. 2015;6:44289\u2013305.","journal-title":"Oncotarget"},{"key":"1666_CR38","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1021\/jm301859s","volume":"56","author":"KM Foote","year":"2013","unstructured":"Foote KM, Blades K, Cronin A, Fillery S, Guichard SS, Hassall L, et al. Discovery of 4-{4-[(3\u2009R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonyl) cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J Med Chem. 2013;56:2125\u201338.","journal-title":"J Med Chem"},{"key":"1666_CR39","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1111\/cas.15845","volume":"114","author":"K Yano","year":"2023","unstructured":"Yano K, Shiotani B. Emerging strategies for cancer therapy by ATR inhibitors. Cancer Sci. 2023;114:2709\u201321.","journal-title":"Cancer Sci"},{"key":"1666_CR40","doi-asserted-by":"publisher","first-page":"eaao2565","DOI":"10.1126\/scitranslmed.aao2565","volume":"10","author":"B Kruspig","year":"2018","unstructured":"Kruspig B, Monteverde T, Neidler S, Hock A, Kerr E, Nixon C, et al. The ERBB network facilitates KRAS-driven lung tumorigenesis. Sci Transl Med. 2018;10:eaao2565.","journal-title":"Sci Transl Med"},{"key":"1666_CR41","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3390\/biom12050647","volume":"12","author":"SL Bearne","year":"2022","unstructured":"Bearne SL, Guo CJ, Liu JL. GTP-Dependent Regulation of CTP Synthase: Evolving Insights into Allosteric Activation and NH3 Translocation. Biomolecules. 2022;12:647.","journal-title":"Biomolecules"},{"key":"1666_CR42","doi-asserted-by":"publisher","first-page":"33727","DOI":"10.1074\/jbc.M110.178566","volume":"285","author":"KM Kassel","year":"2010","unstructured":"Kassel KM, Au DR, Higgins MJ, Hines M, Graves LM. Regulation of human cytidine triphosphate synthetase 2 by phosphorylation. J Biol Chem. 2010;285:33727\u201336.","journal-title":"J Biol Chem"},{"key":"1666_CR43","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s000180300027","volume":"2","author":"M Huang","year":"2003","unstructured":"Huang M, Graves LM. De novo synthesis of pyrimidine nucleotides; emerging interfaces with signal transduction pathways. CMLS, Cell Mol Life Sci. 2003;2:321\u201336.","journal-title":"CMLS, Cell Mol Life Sci"},{"key":"1666_CR44","first-page":"225","volume":"27","author":"M Zhu","year":"2014","unstructured":"Zhu M, Sun W, Wang Y, Meng J, Zhang D, Guo T, et al. Engineered cytidine triphosphate synthetase with reduced product inhibition. Protein Engineering. Des Select. 2014;27:225\u201333.","journal-title":"Des Select"},{"key":"1666_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0140-2","volume":"9","author":"S Carberry","year":"2018","unstructured":"Carberry S, D\u2019Orsi B, Monsefi N, Salvucci M, Bacon O, Fay J, et al. The BAX\/BAK-like protein BOK is a prognostic marker in colorectal cancer. Cell Death Dis. 2018;9:125.","journal-title":"Cell Death Dis"},{"key":"1666_CR46","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/cdd.2017.22","volume":"24","author":"A Gross","year":"2017","unstructured":"Gross A, Katz SG. Non-apoptotic functions of BCL-2 family proteins. Cell Death Differ. 2017;24:1348\u201358.","journal-title":"Cell Death Differ"},{"key":"1666_CR47","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41416-023-02436-2","volume":"130","author":"HA Burris","year":"2024","unstructured":"Burris HA, Berlin J, Arkenau T, Cote GM, Lolkema MP, Ferrer-Playan J, et al. A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours. Br J Cancer. 2024;130:1131\u201340.","journal-title":"Br J Cancer"},{"key":"1666_CR48","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","volume":"30","author":"B Besse","year":"2024","unstructured":"Besse B, Pons-Tostivint E, Park K, Hartl S, Forde PM, Hochmair MJ, et al. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat Med. 2024;30:716\u201329.","journal-title":"Nat Med"},{"key":"1666_CR49","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1200\/JCO.19.02404","volume":"38","author":"TA Yap","year":"2020","unstructured":"Yap TA. Brent O\u2019carrigan ;, Penney MS, Lim JS, Brown JS, De MJ, et al. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. J Clin Oncol. 2020;38:3195\u2013204.","journal-title":"J Clin Oncol"},{"key":"1666_CR50","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1158\/1078-0432.CCR-21-1032","volume":"27","author":"TA Yap","year":"2021","unstructured":"Yap TA, Krebs MG, Postel-Vinay S, El-Khouiery A, Soria JC, Lopez J, et al. Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: A phase I study. Clin Cancer Res. 2021;27:5213\u201324.","journal-title":"Clin Cancer Res"},{"key":"1666_CR51","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","volume":"125","author":"MR Middleton","year":"2021","unstructured":"Middleton MR, Dean E, Evans TRJ, Shapiro GI, Pollard J, Hendriks BS, et al. Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine \u00b1 cisplatin in patients with advanced solid tumours. Br J Cancer. 2021;125:510\u20139.","journal-title":"Br J Cancer"},{"key":"1666_CR52","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014;11:783\u20134.","journal-title":"Nat Methods"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01666-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01666-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01666-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:35:42Z","timestamp":1788514542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01666-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1666"],"URL":"https:\/\/doi.org\/10.1038\/s41418-026-01666-0","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This work was conducted exclusively in established cell lines. Ethics approval was not required for this work.","order":2,"name":"Ethics","label":"Ethics declaration","group":{"name":"EthicsHeading","label":"Ethics"}}]}}